Further to the 4th December 2014 announcement that its orally active lead drug PBI-4050 was due to commence a clinical program designed to evaluate the benefit of PBI-4050 in patients affected by the metabolic syndrome and resulting Type 2 diabetes, the biopharmaceutical corporation announced at the end of last month on 26 January 2015 that Clinical Trial Application clearance had been received from Health Canada. We expect enrolment to commence shortly. According to the International Diabete
03 Feb 2015
ProMetic continues to deliver
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ProMetic continues to deliver
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
03 Feb 2015 -
Author:
Derren Nathan -
Pages:
6
Further to the 4th December 2014 announcement that its orally active lead drug PBI-4050 was due to commence a clinical program designed to evaluate the benefit of PBI-4050 in patients affected by the metabolic syndrome and resulting Type 2 diabetes, the biopharmaceutical corporation announced at the end of last month on 26 January 2015 that Clinical Trial Application clearance had been received from Health Canada. We expect enrolment to commence shortly. According to the International Diabete